Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 1
Eligibility Criteria
Inclusion Criteria: Newly diagnosed type 1 diabetes (within one month of diagnosis). IDDM patients: Prepubescent, adolescent, or early adult patients. Exclusion Criteria: Patients below the age of 3 or over 25. Patients will not be eligible if they are on immunosuppressive or immunostimulatory medications such as azathioprine, oral nicotinamide, superoxide dismutase-desferroxamine, vitamin E, aminoguanidine, oral insulin or other experimental therapies at any time. Patients with a history of alcoholism, renal, cardiac, or pulmonary disease or in whom intellectual functioning is impaired sufficiently to interfere with the understanding of the protocol, or participation in the treatment and evaluation program Patients who are pregnant or nursing, or those who are not willing to practice an acceptable birth control method Patients with abnormal pre-treatment values on WBC or who are receiving potentially hepatotoxic medications
Sites / Locations
- Dept. of Neurology, Rm MSB 7.044 Univ. of Texas-Houston Medical School